CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 4.8: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.28%
Annual Rate
CNY 0.04Paid annual
Payout Ratio
12.5%Sustainable
Last Ex-Dividend
Jun 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.66BCNY990.91M · vs all stocks (USD)
Trailing P/E
39.88xvs Biotechnology peers
Revenue (TTM)
2.26BCNY336.69M · vs all stocks (USD)
Profit Margin
7.18%vs Biotechnology peers
Beta
0.7060xvs all stocks
52-Week Change
-2.80%vs all stocks
Market Capitalization
6.66BCNY990.91M · vs all stocks (USD)
Enterprise Value
5.40BCNY802.38M · vs all stocks (USD)
Trailing P/E
39.88xvs Biotechnology peers
Forward P/E
26.58xvs Biotechnology peers
Price to Sales (TTM)
2.93xvs Biotechnology peers
Price to Book (MRQ)
2.41xvs Biotechnology peers
Enterprise to Revenue
2.38xvs Biotechnology peers
Enterprise to EBITDA
19.77xvs Biotechnology peers
Gross Margin
41.84%vs Biotechnology peers
Profit Margin
7.18%vs Biotechnology peers
Operating Margin
6.74%vs Biotechnology peers
Return on Assets (TTM)
2.58%vs Biotechnology peers
Return on Equity (TTM)
6.36%vs Biotechnology peers
Revenue (TTM)
2.26BCNY336.69M · vs all stocks (USD)
Revenue per Share (TTM)
5.57CNYUpdated Aug 21, 2026Quarterly Revenue Growth
10.80%vs Biotechnology peers
Gross Profit (TTM)
972.50MCNY144.62M · vs all stocks (USD)
EBITDA (TTM)
229.16MCNY34.08M · vs all stocks (USD)
Net Income (TTM)
162.52MCNY24.17M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-13.10%vs Biotechnology peers
Operating Cash Flow (TTM)
246.90MCNY36.72M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
69.72MCNY10.37M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0450CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.28%vs all stocks
Payout Ratio
12.50%vs Biotechnology peers
Minority Interest (Equity)
28.36MCNYFY2025 · Dec 31, 2025Revenue
2.21BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.27BCNYFY2025 · Dec 31, 2025Gross Profit
939.76MCNYFY2025 · Dec 31, 2025Operating Income
191.64MCNY28.50M · vs all stocks (USD)
Pre-tax Income
192.91MCNYFY2025 · Dec 31, 2025Income Tax Expense
21.43MCNYFY2025 · Dec 31, 2025Net Income
171.48MCNYFY2025 · Dec 31, 2025EBIT
194.75MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
376.28MCNYFY2025 · Dec 31, 2025Research & Development
159.93MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
175.34MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.03MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.24MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.84MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.4100CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.4100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
407.19MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
407.19MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
171.48MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-4.54MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-43.80MCNYFY2025 · Dec 31, 2025Free Cash Flow
-147.78MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
475.49MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
171.48MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-18.13MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-62.18MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-134.98MCNYFY2025 · Dec 31, 2025Capital Expenditures
-103.98MCNYFY2025 · Dec 31, 2025Purchase of Investments
-6.05BCNYFY2025 · Dec 31, 2025Sale of Investments
6.05BCNYFY2025 · Dec 31, 2025Other Investing Activity
-2.19MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-109.25MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-20.25MCNYFY2025 · Dec 31, 2025Other Financing Charges
-17.02MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-37.27MCNYFY2025 · Dec 31, 2025Shares Outstanding
416.20MSharesUpdated Aug 21, 2026Float Shares
136.65MSharesUpdated Aug 21, 2026% Held by Insiders
66.01%vs all stocks
% Held by Institutions
6.37%vs all stocks
Total Cash (MRQ)
1.63BCNY242.07M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.02CNYUpdated Aug 21, 2026Total Debt (MRQ)
68.62MCNY10.20M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0254xvs Biotechnology peers
Current Ratio (MRQ)
2.62xvs Biotechnology peers
Book Value per Share (MRQ)
6.61CNYUpdated Aug 21, 2026Total Assets
3.94BCNY586.29M · vs all stocks (USD)
Total Current Assets
2.92BCNYFY2025 · Dec 31, 2025Total Liabilities
1.26BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.03BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
52.42MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.21BCNYFY2025 · Dec 31, 2025Cash
472.96MCNYFY2025 · Dec 31, 2025Cash Equivalents
8.58MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
481.54MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.29BCNYFY2025 · Dec 31, 2025Accounts Receivable
600.02MCNYFY2025 · Dec 31, 2025Inventory
294.68MCNYFY2025 · Dec 31, 2025Accounts Payable
250.65MCNYFY2025 · Dec 31, 2025Short-term Debt
35.06MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.21MCNYFY2025 · Dec 31, 2025Long-term Debt
36.39MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.01MCNYFY2025 · Dec 31, 2025Common Stock (Book)
416.20MCNYFY2025 · Dec 31, 2025Retained Earnings
1.10BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.68BCNY398.73M · vs all stocks (USD)
Treasury Stock
144.16MCNYFY2025 · Dec 31, 202552-Week Low
11.46CNYUpdated Aug 21, 202652-Week High
18.24CNYUpdated Aug 21, 202652-Week Change
-2.80%vs all stocks
Beta
0.7060xvs all stocks
50-Day MA
13.34CNYUpdated Aug 21, 2026200-Day MA
14.18CNYUpdated Aug 21, 2026Avg 10-Day Volume
16.57MSharesUpdated Aug 21, 2026Avg 30-Day Volume
8.41MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.4000CNYUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.42Profit Margin: 0.07
Financial Health
Altman Z-Score 4.8: safe zoneNotable
Altman Z-Score: 4.80
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
BioAge Labs, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Ausun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cronos Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CK Life Sciences Int'l.,
Tier 1ProductionApproval-Gated PipelineFlowInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Dexcom Inc.
3 interpretationsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital Elevated
Harmony Biosciences Holdings, Inc.
3 interpretationsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital Elevated
Incyte Corporation
3 interpretationsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital Elevated